High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer
High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer
复制标题
DOI：
10.3892/or.2020.7610
复制
发表时间：
2020-07-01
期刊：
影响因子：
4.2
通讯作者：
Wada, Satoshi
中科院分区：
文献类型：
--
作者：
Ohkuma, Ryotaro;Yada, Erica;Wada, Satoshi
胰腺癌预后极差，需要发现新的治疗和预后标志物。聚合免疫球蛋白受体（pIgR）是粘膜免疫系统的关键组成部分，在几种癌症中表达增加。然而，其在胰腺癌中的临床意义尚不清楚。本研究评估了pIgR在胰腺癌手术切除后患者的预后价值，确定pIgR的表达与预后不良相关。建立了10个胰腺癌患者来源的异种移植物（PDX）系，随后对这些系在标准化疗后的肿瘤组织进行了下一代测序。对77例胰腺癌组织进行了化疗耐药相关分子的免疫组织化学分析。抗肿瘤药物治疗的PDX组pIgR mRNA表达高于未治疗组。77例胰腺癌患者组织标本中pIgR高表达与预后不良显著相关，是预测预后不良的独立预后因素。高水平的pIgR mRNA和蛋白水平是独立的预后因素，提示pIgR可能是胰腺癌患者预后不良的一个新的预测因子。
Pancreatic cancer has extremely poor prognosis, warranting the discovery of novel therapeutic and prognostic markers. The expression of polymeric immunoglobulin receptor (pIgR), a key component of the mucosal immune system, is increased in several cancers. However, its clinical relevance in pancreatic cancer remains unclear. In the present study, the prognostic value of pIgR in pancreatic cancer patients after surgical resection was assessed and it was determined that the expression of pIgR was correlated with poor prognosis. Ten pancreatic cancer patient-derived xenograft (PDX) lines were established, followed by next-generation sequencing of tumor tissues from these lines after standard chemotherapy. Immunohistochemical analysis of chemoresistance-related molecules using 77 pancreatic cancer tissues was also performed. The expression of pIgR mRNA in the PDX group treated with anticancer drugs was higher than in the untreated group. High pIgR expression in tissue specimens from 77 pancreatic cancer patients was significantly associated with poor prognosis and was revealed to be an independent prognostic factor, predicting poor outcomes. High pIgR mRNA and protein levels were independent prognostic factors, indicating that pIgR could be a novel predictor for poor prognosis of pancreatic cancer patients.